Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 630 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... August 11, 2021 The Grace Project Helps Breast Cancer Survivors Practice Body Acceptance and... July 27, 2021 The vaccination of a generation? – That Cancer Conversation December 9, 2021 Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 Load more HOT NEWS Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy Charity ‘looks to the future with renewed optimism’ High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint...
